Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/16/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. M. Roy First MD

Wrong Dr. M. Roy First MD?

Vice President

Astellas Pharma Global Development , Inc.
Local Address: Northbrook, Illinois, United States
Astellas Pharma Inc.
2-5-1 Nihonbashi-Honcho Chuo-ku
Tokyo, Tokyo 103-8411

Company Description: Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of...   more

Employment History


  • M.D.
41 Total References
Web References
Roy First, vice president ..., 21 Mar 2014 [cached]
Roy First, vice president and therapeutic area head of transplantation for Astellas Pharma Global Development in Northbrook, Ill., says Schroeder and CTI have developed a solid reputation in their specialty niches, especially transplant medicine.
NATCO - The Organization for Transplant Professionals, 28 Feb 2012 [cached]
An Interview with M. Roy First, MD NATCO Research Awards Legislative Update
An Interview with M. Roy First
The 2013 American Society of Transplantation (AST) Lifetime Achievement Award was presented to M. Roy First, M.D. at the American Transplant Congress (ATC) meeting in Seattle, Wash. NATCO received a call offering the opportunity to interview Dr. First in the Press Room at the Convention Center. The call was appropriately forwarded to me to conduct the interview as part of our "Courage and Character, Leaders and Legends" series. Prior to most interviews, there is time to read publications written by the person to be interviewed. With short notice, only several articles were scanned but the opportunity to interview Dr. First was not going to be missed. I hurried to the Convention Center and arrived in time to see an impressive looking white haired man in a suit and tie being taken to the press room. I introduced myself to Dr. First and his staff, and we began our interview.
Dr. First's delightful South African accent made the interview even more interesting and pleasant. Having been born and raised in South Africa, Dr. First received his medical education in Johannesburg. He explained this educational program spanned six years at the University of Witwatersrand.
Dr. First was invited to join him in 1974 for a clinical fellowship in nephrology. Soon after completing his fellowship he was appointed assistant professor of medicine in the Division of Nephrology at the University of Cincinnati. Over the next 30 years in Cincinnati, his career flourished as he was promoted to full professor and director of transplantation. Steroid withdrawal became a great interest of Dr. First. He was involved with several studies that provided patients with steroid free therapies once withdrawn (1-4). These trials have led to less diabetes. Although there have been more rejection episodes in many of the steroid withdrawal recipients, long term graft outcomes have been similar in comparison with those patients who continued on steroids. We discussed how successful these programs have been in kidney and liver transplantation but not with thoracic transplantation. Our conversation quickly turned to immunosuppression and ways to manage the immune system. We discussed various tolerance studies conducted by Drs. Newell, Kirk and Starzl (5, 6) and how the road to tolerance has been paved with many disappointments but continued determination with numerous active protocols in the United States, Europe and Australia.
In addition to his role in nephrology at the University of Cincinnati, Dr. First also became involved in what is now known as the Israel Penn International Transplant Tumor Registry (7). He recalled that Dr. Penn presented a paper on four cases of Post Transplant Lymphoproliferative Disease (PTLD) at the first meeting of the International Transplant Society held in Paris in 1966. After his presentation, several physicians described similar experiences with this disease he called PTLD.
During his 30 years at the University of Cincinnati, Dr. First also held many professional leadership roles. In 1982 he met with a group of nephrologists and immunologists at meeting of the American Society of Transplant Surgeons in Chicago in 1982. They had a small conference room and began developing the structure of the American Society of Transplant Physicians (ASTP). A few years later he was elected President of ASTP, a position he held from 1990-1991. This association was later renamed as the American Society of Transplantation (AST). He served on numerous AST committees over the years and was one of the founders of the American Journal of Transplantation. In the 1990s he also served on many UNOS committees and has been a reviewer for the National Institute of Health Data and Safety Monitoring Board (DSMB) for clinical trials in transplantation. He has more than 400 publications in peer-reviewed journals as well as chapters in textbooks.
In 2002, Dr. First joined the pharmaceutical industry where he now serves as the Vice President and Therapeutic Area Head of Transplantation at Astellas. He continues to participate in publications involving trials of new immunosuppressive agents.
Dr. First has truly been an influential leader in the field of transplantation. His passion for understanding the immune system and finding medications to better manage and prevent rejection, led him to Astellas where he could influence studies to improve the outcomes of transplantation. With his work in the Tumor Registry he also has a clear understanding that we need to find medications that can manage the immune system in ways that will not increase the risk of malignancies. In receiving the prestigious Lifetime Achievement Award by AST this year, Dr. First has been recognized by his peers as having demonstrated characteristics of leadership with the courage to move our science for immunosuppression forward.
"The NDA acceptance for tacrolimus ..., 4 Dec 2012 [cached]
"The NDA acceptance for tacrolimus extended release capsules marks an important step toward addressing the unmet treatment need for transplant recipients who have difficulty controlling their immunosuppression drug levels with existing products," said Roy First, MD, Astellas Global Therapeutic Area Head for Transplantation.
"After more than 20 years of ..., 28 May 2009 [cached]
"After more than 20 years of commitment to the fields of immunology and transplantation, Astellas remains dedicated to the advancement of the science of immunosuppression to enhance the care of transplant patients," said M. Roy First, M.D., Vice President, Therapeutic Area Head, Transplantation for Astellas.
Astellas Receives FDA Approval of Prograf(R) (Tacrolimus) for Use in Heart Transplant Recipients, 31 Mar 2006 [cached]
"The approval of Prograf for use in heart transplant patients represents a major milestone for both Astellas and the transplant community," said M. Roy First, M.D., Vice President, Medical Affairs for Astellas Pharma US, Inc.
Other People with the name "First":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.